Eiger ends PhI­II he­pati­tis delta tri­al over safe­ty con­cerns — and the search for treat­ment part­ner

Eiger Bio­Phar­ma­ceu­ti­cals is end­ing a Phase III tri­al in­ves­ti­gat­ing its treat­ment in liv­er in­fec­tions caused by the he­pati­tis D virus over safe­ty con­cerns, just a few months af­ter it laid off 25% of its em­ploy­ees and cut R&D spend­ing to the pro­gram.

Eiger was in­ves­ti­gat­ing pegin­ter­fer­on lamb­da in pa­tients with chron­ic he­pati­tis delta, a liv­er in­fec­tion caused by the he­pati­tis D virus. He­pati­tis D on­ly oc­curs in peo­ple who are al­so in­fect­ed with the he­pati­tis B virus, ac­cord­ing to the CDC. It re­sults in the most se­vere form of hu­man vi­ral he­pati­tis, for which there is no ap­proved ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER